This article discusses the recent approval of the first over-the-counter naloxone nasal spray for use in reversing opioid overdoses. The U.S. Food and Drug Administration (FDA) has approved the first over-the-counter (OTC) naloxone nasal spray, Narcan, to help prevent opioid overdoses. The nasal spray is intended for use in adults and adolescents, and the FDA […]
FDA Approves OTC Naloxone Read More »
The ADA has issued a FAQ (frequently asked questions) providing additional information regarding the 2022 Omnibus Bill with provisions for the MATE Act – which included a controlled substance education requirement for continuing DEA registration. The FAQ suggests further information and guidance will be forthcoming by the end of March. The Act contains exclusions and
It has come to our attention a little known provision of the federal omnibus bill approved in the waning hours of 2022 included a requirement that could impact your practice if not properly managed. The Medication Access and Training Expansion (MATE) Act, which aims to improve access to medications and expand training for healthcare professionals
A recent CDC analysis shows that antihistamines, particularly first-generation H1 subtype antihistamines like diphenhydramine, play a role in drug overdoses. Opioids were involved in most cases, and naloxone may not work with antihistamines. Continual monitoring is important.
Antihistamines A common Contributor In Opioid Overdose Deaths? Read More »
Discover the greatest sage wisdom through a must-read book. Purchase it and start putting it into practice today.
Healthcare professionals have been alerted by the FDA to the dangers of patients being exposed to xylazine, a veterinary sedative, in illicit drugs. The FDA advises healthcare professionals to report any adverse events related to xylazine.
Fentanyl is now the leading cause of overdose deaths among young people, with a nearly 500% increase in deaths among those aged 25 and under. Learn more.
NC Policy Watch – A closer look at the mounting toll of fentanyl on the nation’s youth Read More »
Congress has passed the FDA Modernization Act 2.0 as part of the recent omnibus bill, removing the requirement to use animal testing in drug development. This allows drug companies to use alternative safety-testing models, such as cell-based assays, organ chips and microphysiological systems, and sophisticated computer modeling. Proponents state these alternatives are cost-effective and provide
FDA Modernization Act 2.0 Read More »
For over two decades, the opioid crisis in the United States has been an urgent health care emergency. Initially driven by over-prescription of pharmaceutical opioids, this has evolved into a “fourth wave” marked by poly-substance use, combining opioids and methamphetamine, resulting in record-high deaths year after year. The Covid-19 pandemic has made the situation even
The Fourth Wave Of The Opiate Crisis Read More »
Here are a few of our ideas for continuing education requirements related to mental health and substance abuse:
Main Menu
User Menu
